hydroxychloroquine

health

Doc Who Used Hydroxychloroquine Met Standard of Care; More

Doctor Who Treated COVID Patients With Hydroxychloroquine Met Standard of Care, Officials Say

A complaint against a Texas doctor who was reported for malpractice to the state medical board for apparently prescribing hydroxychloroquine to treat several coronavirus patients has been dismissed, says a story in The Texan, a subscription-based news organization.

The doctor, Richard Urso, MD, a Houston ophthalmologist, has been an outspoken proponent of hydroxychloroquine and is a member of America’s Frontline Doctors, a group that gained attention this summer for airing what some in the more mainstream medical community regarded as “outrageous claims” about the virus and its treatment.

In the complaint against him, Urso was accused of violating the state’s Medical Practice Act, which sets out the rules for practicing doctors and other healthcare professionals.



In an October 16 letter to Urso, though, the Texas Medical Board (TMB) said it was dismissing the complaint against him because it had “determined there was insufficient evidence to prove that a violation of the Medical Practice Act [had] occurred.” Although the board didn’t specifically mention hydroxychloroquine, it noted that Urso’s care of three patients was “appropriate” and that his use of social media to “discuss treatments for COVID-19” met the standard of care.

Why did the TMB feel compelled to investigate the complaint against Urso — or any doctor who uses alternative medicine to treat COVID-19? The answer is in an earlier press release.

On July 31, the TMB advised such doctors to tread carefully, urging them to refer to applicable “laws and Board rules.” It further noted: “If the Board were to receive a complaint, it would be reviewed following the Board’s standard enforcement process…. The Board may also investigate complaints for false, misleading or deceptive advertising, which could include for assuring a permanent cure for an incurable disease.”

The next month, TMB President Sherif Z. Zaafran, MD, an anesthesiologist, felt the need to further clarify the board’s position: “The Texas Medical Board has never prohibited the use of Hydroxychloroquine alone, or in conjunction with other drugs, for the treatment of COVID-19. In fact, the TMB does not prohibit any drug or treatment…. The off-label use of Hydroxychloroquine as an alternative therapy for COVID-19 patients is completely permissible” as long as “physicians…provide full disclosure of treatment options, side effects, and obtain informed consent.”

In mid-June, the US Food and Drug Administration (FDA) revoked the emergency use authorization of hydroxychloroquine (and chloroquine) to treat COVID-19. Earlier, the FDA cautioned against the use of either drug “outside of the hospital setting or a clinical trial due to risk of arrhythmias.”

Case Involving Nursing Assistant Who Murdered Seven Vets Sees Settlement With Families

The federal government has reached a tentative settlement with the families of six veterans who died at the Louis A. Johnson Veterans Affairs Medical Center, in Clarksburg, West Virginia, according to a news report on CNN.com, among other news outlets.

The government’s deal follows a July guilty plea by former VA healthcare worker Reta Mays, who admitted to killing

Read More
health

Trump bypassed state officials to distribute hydroxychloroquine to pharmacies

Trump trade adviser Peter Navarro wanted to make sure the administration’s top vaccine expert would be on board with a White House plan to distribute the unproven drug to hard-hit cities.

“The first thing out of his mouth was, ‘I want to know what team you are on,’ ” recalled Rick Bright, who at the time was responsible for stockpiling drugs for medical emergencies as director of the federal Biomedical Advanced Research and Development Authority.

The immunologist, who later filed a whistleblower complaint against the administration, said in an interview with The Washington Post that he told Navarro he was on the side of medical evidence. Navarro, Bright said, replied, “I won’t hold it against you, but we need to move this forward.” Navarro declined to comment on Bright’s account.

The White House decision to set aside the mandatory safety controls put in place by the Food and Drug Administration fueled one of the most disputed initiatives in the administration’s response to the pandemic: the distribution of millions of ineffective, potentially dangerous pills from a federally controlled cache of drugs called the Strategic National Stockpile.

Over a span of four days in early April, the White House ordered the distribution of 23 million hydroxychloroquine tablets from the stockpile to a dozen states, enough pills for 1.4 million covid-19 patients, according to public records obtained by The Post in response to a Freedom of Information Act request.

The Post review found that the process was marked by haphazard planning, little or no communication to local authorities about the flow of pills into their communities, and a lack of public accounting about where they ended up.

The documents also demonstrate the steps the administration took to bypass the FDA’s March 28 authorization for emergency use of the tablets, which limited their use to hospitals and clinical drug trials. According to FDA guidance at the time, state authorities were supposed to request stockpile supplies before they were delivered. But interviews and documents show that procedure was not followed in many cases.

The White House ordered more than a third of the tablets sent to the three major drug distributors in the United States with instructions to deliver them not only to hospitals but also retail pharmacies in five U.S. cities, despite the FDA controls, according to public records.

“At the direction of the White House, SNS did a one-time shipment of hydroxychloroquine to several commercial distributors to support further distribution of hydroxychloroquine directly to hospitals and retail pharmacies in the hard hit areas of NYC, Detroit, Chicago, and New Orleans,” a senior analyst at HHS said in an internal email exchange.

One major wholesaler said it shipped to long-term care facilities, which also were not covered in the FDA’s emergency authorization. All three distributors told The Post they did not ship to retail pharmacies, despite the administration’s request.

The Department of Health and Human Services, which oversees the stockpile, confirmed in an email to The Post that the pills were supposed to go

Read More